$1000 per mile boosts cancer research and treatment

Race raises more than $10,500 for UNC Lineberger

Chapel Hill, NC – The Wachovia Tar Heel 10 miler and Fleet Feet 4+ mile run attracted more than 3500 runners to Chapel Hill on April 9th.  Among the crowds were UNC researchers, doctors, nurses and other staff – all running a hilly course to benefit cancer research and treatment at UNC Lineberger Comprehensive Cancer Center.  The race raised more than $10,000 through entries, charitable contributions and charity slots, opened after the race sold out.

“We are thrilled to have been chosen a charity partner, along with the YMCA’s We Build People Campaign, by Endurance Magazine, which produces the race,” said UNC Lineberger Director Shelley Earp, MD.

“All of us are working to make Chapel Hill and North Carolina a healthier place to live and community support is very important to all of the scientists, physicians and health care providers who work hard every day to ease the burden of cancer for all North Carolinians.”

More than a dozen faculty and staff came out for ‘Team Lineberger’ – running to show solidarity with their patients fighting cancer, promote healthy lifestyles and to thank Endurance magazine and race sponsors for their support.

About Endurance Magazine

Endurance Magazine is the premier resource for active lifestyles in the Carolinas. Focused on educating, inspiring, and motivating athletes of all levels and abilities, Endurance Magazine offers compelling and immediately useful editorial and produces life-changing endurance events including the Wachovia Tar Heel 10 Miler and Ramblin’ Rose Women’s Triathlon Tour. For more information go to www.endurancemag.com.

About UNC Lineberger Comprehensive Cancer Center

As one of only 40 National Cancer Institute-designated comprehensive cancer centers, UNC Lineberger has brought together some of the most exceptional physicians and scientists in the country to combat cancer.  The Center’s efforts span the spectrum from the laboratory to global practice, meaning that we work to understand the causes of cancer at the genetic and population levels, conduct groundbreaking laboratory research, and pioneer innovative clinical trials that bring the latest discoveries to patient bedsides.  For more information, visit unclineberger.org.